Sequential Regenerative Activation of Cavernosal Tissue using Low-intensity Extracorporeal Shockwave Therapy and Systemic Exosome Administration in Neurogenic Erectile Dysfunction
Original Article | Vol 6 | Issue 1 | January-June 2026 | page: 9-13 | César Eisner
DOI: https://doi.org/10.13107/jrs.2026.v06.i01.191
Open Access License: CC BY-NC 4.0
Copyright Statement: Copyright © 2026; The Author(s).
Submitted Date: 28 Mar 2026, Review Date: 02 Apr 2026, Accepted Date: April 2026 & Published: 30 June 2026
Author: César Eisner [1]
[1] Shockwave Argentina, Ciudad Autónoma de Buenos Aires, Argentina.
Address of Correspondence
Dr. César Eisner,
Shockwave Argentina, Ciudad Autónoma de Buenos Aires, Argentina.
E-mail: shockwaveargentina@gmail.com
Abstract
Introduction: Neurogenic erectile dysfunction (NED) results from injury to the cavernous nerves and is characterized by impaired nitrergic signaling, tissue hypoxia, endothelial dysfunction, and progressive fibrotic remodeling of the corpora cavernosa. Current treatments primarily address symptoms rather than underlying regenerative mechanisms.
Objective: The objective of the study is to propose a mechanistically guided regenerative therapeutic model combining low-intensity extracorporeal shockwave therapy (Li-ESWT) with systemic administration of mesenchymal stem cell-derived exosomes to promote neural repair and restore the cavernosal neurovascular microenvironment.
Materials and Methods: A conceptual therapeutic protocol is described based on the biological interaction between shockwave-induced mechanotransduction and chemotactic recruitment of regenerative extracellular vesicles through activation of the stromal-derived factor-1 (SDF-1)/C-X-C chemokine receptor type 4 (CXCR4) axis.
Results: Li-ESWT induces transient upregulation of angiogenic and chemotactic mediators including vascular endothelial growth factor, endothelial nitric oxide synthase, and SDF-1, generating a temporary regenerative microenvironment. Systemically administered exosomes expressing CXCR4 receptors may preferentially migrate toward tissues with increased SDF-1 expression, facilitating targeted delivery of regenerative signaling molecules capable of promoting neural regeneration, angiogenesis, and antifibrotic modulation.
Conclusion: Sequential activation of tissue mechanotransduction followed by systemic exosome administration may represent a biologically guided regenerative strategy for NED. This approach constitutes the conceptual basis for the PROSIN protocol, a multimodal regenerative therapy designed to restore penile neurovascular function.
Keywords: Neurogenic erectile dysfunction, Extracorporeal shockwave therapy, Exosomes, Regenerative medicine, Stromal-derived factor-1 C-X-C chemokine receptor type 4 axis, Cavernous nerve regeneration
References
1. Burnett AL, Nehra A, Breau RH, Culkin DJ, Faraday MM, Hakim LS, et al. Erectile Dysfunction: AUA Guideline. J Urol. 2018 Sep;200(3):633-641. doi: 10.1016/j.juro.2018.05.004. Epub 2018 May 7.
2. Montorsi F, Burnett AL. Erectile dysfunction after radical prostatectomy. BJU Int. 2004 Jan;93(1):1-2. doi: 10.1111/j.1464-410x.2004.04542.x. PMID: 14678354.Malavige LS, Levy JC. Erectile dysfunction in diabetes mellitus. J Sex Med. 2009.
3. Burnett AL. Nitric oxide regulation of penile erection: biology and therapeutic implications. J Androl. 2002 Sep-Oct;23(5):S20-6. PMID: 12236169.
4. Andersson KE. Mechanisms of penile erection and basis for pharmacological treatment of erectile dysfunction. Pharmacol Rev. 2011 Dec;63(4):811-59.
doi: 10.1124/pr.111.004515.
5. Iacono F, Giannella R, Somma P, Manno G, Fusco F, Mirone V. Histological alterations in cavernous tissue after radical prostatectomy. J Urol. 2005 May;173(5):1673-6. doi: 10.1097/01.ju.0000154356.76027.4f.
6. User HM, Hairston JH, Zelner DJ, McKenna KE, McVary KT. Penile weight and cell subtype specific changes in a post-radical prostatectomy model of erectile dysfunction. J Urol. 2003 Mar;169(3):1175-9. doi: 10.1097/01.ju.0000048974.47461.50.
7. Gonzalez-Cadavid NF. Mechanisms of penile fibrosis. J Sex Med. 2009 Mar;6 Suppl 3:353-62. doi: 10.1111/j.1743-6109.2008.01195.x
8. Cellek S, Cameron NE, Cotter MA, Muneer A. Pathophysiology of diabetic erectile dysfunction: potential contribution of vasa nervorum and advanced glycation endproducts. Int J Impot Res. 2013 Jan;25(1):1-6.
doi: 10.1038/ijir.2012.30.
9. Moore CR, Wang R. Pathophysiology and treatment of diabetic erectile dysfunction. Asian J Androl. 2006 Nov;8(6):675-84. doi: 10.1111/j.1745-7262.2006.00223.x.
10. Salonia A, Bettocchi C, Boeri L, Capogrosso P, Carvalho J, Cilesiz NC, et al. EAU Working Group on Male Sexual and Reproductive Health. European Association of Urology Guidelines on Sexual and Reproductive Health-2021 Update: Male Sexual Dysfunction. Eur Urol. 2021 Sep;80(3):333-357. doi: 10.1016/j.eururo.2021.06.007.
11. Huang SA, Lie JD. Phosphodiesterase-5 (PDE5) Inhibitors In the Management of Erectile Dysfunction. P T. 2013 Jul;38(7):407-19.
12. Vlaicu AG, Mirvald C, Najjar S, Garaz R, Tsaur I, Sinescu I, Surcel C. Intracavernous Injection Therapy as Second-Line Treatment for ED After Radical Prostatectomy: A Literature Review. Medicina (Kaunas). 2026 Jan 4;62(1):111. doi: 10.3390/medicina62010111.
13. Qin F, Wang S, Li J, Wu C, Yuan J. The Early Use of Vacuum Therapy for Penile Rehabilitation After Radical Prostatectomy: Systematic Review and Meta-Analysis. Am J Mens Health. 2018 Nov;12(6):2136-2143. doi: 10.1177/1557988318797409.
14. Kim S, Cho MC, Cho SY, Chung H, Rajasekaran MR. Novel Emerging Therapies for Erectile Dysfunction. World J Mens Health. 2021 Jan;39(1):48-64. doi: 10.5534/wjmh.200007.
15. Kitrey ND, Vardi Y, Appel B, Shechter A, Massarwi O, Abu-Ghanem Y, et al. Low Intensity Shock Wave Treatment for Erectile Dysfunction-How Long Does the Effect Last? J Urol. 2018 Jul;200(1):167-170.
doi: 10.1016/j.juro.2018.02.070.
16. Ergun O, Kim K, Kim MH, Hwang EC, Blair Y, Gudeloglu A, Parekattil S, Dahm P. Low‐intensity shockwave therapy for erectile dysfunction. Cochrane Database Syst Rev. 2023 Sep 20;2023(9):CD013166.
doi: 10.1002/14651858.CD013166.pub2.
17. de Oliveira PS, Ziegelmann MJ. Low-intensity shock wave therapy for the treatment of vasculogenic erectile dysfunction: a narrative review of technical considerations and treatment outcomes. Transl Androl Urol. 2021 Jun;10(6):2617-2628. doi: 10.21037/tau-20-1286.
18. Eisner C, Salas M, Moya D. Fundamentals of the Treatment of Male Erectile
Dysfunctions with Low Intensity Shockwaves. Journal of Regenerative Science |December 2021; 1(1): 26-29. doi: 10.13107/jrs.2021.v01.i01.015
19. Feng H, Peng W, Deng Z, Liu J, Wang T. Erectile dysfunction and exosome therapy. Front Endocrinol (Lausanne). 2023 Mar 9;14:1123383.
doi: 10.3389/fendo.2023.1123383.
20. Zhu Y, Jiang T, Yao C, Zhang J, Sun C, Chen S, Chen M. Effects of stem cell-derived exosome therapy on erectile dysfunction: a systematic review and meta-analysis of preclinical studies. Sex Med. 2023 Mar 1;11(2):qfac019.
doi: 10.1093/sexmed/qfac019.
21. Kim MY, Jo MS, Choi SG, Moon HW, Park J, Lee JY. Repeated Injections of Mesenchymal Stem Cell-Derived Exosomes Ameliorate Erectile Dysfunction in a Cavernous Nerve Injury Rat Model. World J Mens Health. 2024 Oct;42(4):787-796. doi: 10.5534/wjmh.230218.
22. d’Agostino MC, Craig K, Tibalt E, Respizzi S. Shock wave as biological therapeutic tool: From mechanical stimulation to recovery and healing, through mechanotransduction. Int J Surg. 2015 Dec;24(Pt B):147-53.
doi: 10.1016/j.ijsu.2015.11.030.
23. Moya D, Ramón S, Schaden W, Wang CJ, Guiloff L, Cheng JH. The Role of Extracorporeal Shockwave Treatment in Musculoskeletal Disorders. J Bone Joint Surg Am. 2018 Feb 7;100(3):251-263. doi: 10.2106/JBJS.17.00661.
24. Qiu X, Lin G, Xin Z, Ferretti L, Zhang H, Lue TF, Lin CS. Effects of low-energy shockwave therapy on the erectile function and tissue of a diabetic rat model. J Sex Med. 2013 Mar;10(3):738-46. doi: 10.1111/jsm.12024.
25. Ortaç M, Küçükergin C, Salabaş E, Seçkin Ş, Kadıoğlu A. Effect of low-energy shockwave therapy on angiogenic factors in the penile tissue of diabetic rats. Turk J Urol. 2017 Jun;43(2):130-134. doi: 10.5152/tud.2017.35002.
26. Cheng M, Qin G. Progenitor cell mobilization and recruitment: SDF-1, CXCR4, α4-integrin, and c-kit. Prog Mol Biol Transl Sci. 2012;111:243-64.
doi: 10.1016/B978-0-12-398459-3.00011-3.
27. Ratajczak MZ, Serwin K, Schneider G. Innate immunity derived factors as external modulators of the CXCL12-CXCR4 axis and their role in stem cell homing and mobilization. Theranostics. 2013;3(1):3-10. doi: 10.7150/thno.4621.
28. Ling L, Hou J, Liu D, Tang D, Zhang Y, Zeng Q, Pan H, Fan L. Important role of the SDF-1/CXCR4 axis in the homing of systemically transplanted human amnion-derived mesenchymal stem cells (hAD-MSCs) to ovaries in rats with chemotherapy-induced premature ovarian insufficiency (POI). Stem Cell Res Ther. 2022 Feb 23;13(1):79. doi: 10.1186/s13287-022-02759-6.
29. Li J, Deng T, Zhu S, Xie P, Wang W, Zhou H, Xu C. The SDF-1/CXCR4 axis is involved in adipose-derived stem cell migration. Neurourol Urodyn. 2024 Nov;43(8):2279-2289. doi: 10.1002/nau.25571.
30. Bianchi ME, Mezzapelle R. The Chemokine Receptor CXCR4 in Cell Proliferation and Tissue Regeneration. Front Immunol. 2020 Aug 28;11:2109. doi: 10.3389/fimmu.2020.02109.
31. Liesveld JL, Sharma N, Aljitawi OS. Stem cell homing: From physiology to therapeutics. Stem Cells. 2020 Oct 1;38(10):1241-1253. doi: 10.1002/stem.3242.
32. Théry C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002 Aug;2(8):569-79. doi: 10.1038/nri855.
33. Tkach M, Théry C. Communication by extracellular vesicles: Where we are and where we need to go. Cell. 2016 Mar 10;164(6):1226-1232.
doi: 10.1016/j.cell.2016.01.043.
34. Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020 Feb 7;367(6478):eaau6977.
doi: 10.1126/science.aau6977.
35. Nikfarjam S, Rezaie J, Zolbanin NM, Jafari R. Mesenchymal stem cell derived-exosomes: a modern approach in translational medicine. J Transl Med. 2020 Nov 27;18(1):449. doi: 10.1186/s12967-020-02622-3.
36. Li K, Li R, Zhao Z, Feng C, Liu S, Fu Q. Therapeutic potential of mesenchymal stem cell-derived exosomal miR-296-5p and miR-337-3p in age-related erectile dysfunction via regulating PTEN/PI3K/AKT pathway. Biomed Pharmacother. 2023 Nov;167:115449. doi: 10.1016/j.biopha.2023.115449.
37. Ping X, Zhou H, Zhang Y, Liu X, Tao T, Liu Q, Feng S, Lou K. The New Approach to Treating Erectile Dysfunction: Stem Cell-Derived Extracellular Vesicles. Int J Nanomedicine. 2025 Sep 13;20:11249-11266. doi: 10.2147/IJN.S547834.
38. Wang W, Li Y, Zhang C, Zhou H, Li C, Cheng R, Chen X, Pu Y, Chen Y. Small Extracellular Vesicles from Young Healthy Human Plasma Inhibit Cardiac Fibrosis After Myocardial Infarction via miR-664a-3p Targeting SMAD4. Int J Nanomedicine. 2025 Jan 13;20:557-579. doi: 10.2147/IJN.S488368.
39. Wang X, Li Y, Ye J, Guo X, Xie M, Wang J. Exosomes derived from ADSCs suppress the fibrosis process of derma in secondary lymphedema. Sci Rep. 2026 Jan 13;16(1):4179. doi: 10.1038/s41598-025-34280-0.
40. Xiao Y, Hoorain I, Zhang L, Bellusci S, Jin X, Yang H, Zhang JS. Unpacking the anti-fibrotic arsenal: molecular mechanisms and therapeutic translation of MSC-derived exosomes in pulmonary fibrosis. Front Immunol. 2025 Dec 12;16:1725041. doi: 10.3389/fimmu.2025.1725041.
| How to Cite this article: Eisner C | Sequential Regenerative Activation of Cavernosal Tissue using Lowintensity Extracorporeal Shockwave Therapy and Systemic Exosome Administration in Neurogenic Erectile Dysfunction. | Journal of Regenerative Science | Jan-Jun 2026; 6(1): 09-13. |
